27 November 2017 - BioMarin today announced that it has entered into a definitive agreement to sell the rare paediatric disease priority review voucher it obtained in April of this year for a lump sum payment of $125,000,000. 

The company received the voucher under a U.S. FDA program intended to encourage the development of treatments for rare paediatric diseases. BioMarin was awarded the voucher when it received approval of Brineura, a new biological product for patients with late infantile neuronal ceroid lipofuscinosis type 2, also known as tripeptidyl peptidase 1 deficiency, a form of Batten disease.

The transaction remains subject to customary closing conditions, including anti-trust review.

Read BioMarin press release